More on JNJ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $278.43 |
|
|||
| Open | $275.13 | ||||
| 52 Wk High | $126.07 | ||||
| 52 Wk Low | $94.28 | ||||
| Day High | $277.80 | ||||
| Day Low | $274.75 | ||||
| P/E | 57.22 | ||||
| EPS | $4.81 | ||||
| Volume | 4,320,320 | ||||
- Form 4 JOHNSON & JOHNSON For: Sep 02 Filed by: Schmid Timothy
- Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
- Form 144 JOHNSON & JOHNSON Filed by: Schmid Timothy
- Form 3 JOHNSON & JOHNSON For: Sep 01 Filed by: Cavanaugh Thomas
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- FDA approves Johnson & Johnson drug for rare blood disorder
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- Form 4 JOHNSON & JOHNSON For: Aug 17 Filed by: Taubert Jennifer L
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
Entities mentioned with JNJ
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
